Clinical efficacy of Salofalk combined with beneficial bacteria in patients with ulcerative colitis

World Chinese Journal of Digestology

Volumn , Issue 22, 2014, Pages 3344-3348

  Liu, Ping ^a   Sun, Liang ^a   Zhang, Zhen Hai ^a   Zhang, Peng ^a   Zhang, Jian ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Beneficial bacteria; Combination therapy; Inflammation; Salofalk; Ulcerative colitis

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 8; MESALAZINE; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BENEFICIAL ORGANISM; BIFIDOBACTERIUM; COLONOSCOPY; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; ULCERATIVE COLITIS;

EID: 84905392455     PISSN: 10093079     EISSN: None     Source Type: Journal    
DOI: 10.11569/wcjd.v22.i22.3344     Document Type: Article

References (9)

1. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105: 501-523; quiz 524 [PMID: 20068560]
2. Meucci G, Fasoli R, Saibeni S, Valpiani D, Gullotta R, Colombo E, D'Incà R, Terpin M, Lombardi G. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. Inflamm Bowel Dis 2012; 18: 1006-1010 [PMID: 21830282 DOI: 10.1002/ibd.21838]
3. Ardizzone S, Cassinotti A, Duca P, Mazzali C, Penati C, Manes G, Marmo R, Massari A, Molteni P, Maconi G, Porro GB. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011; 9: 483-489. e3 [PMID: 21195796]
4. Cucchiara S, Iebba V, Conte MP, Schippa S. The microbiota in inflammatory bowel disease in different age groups. Dig Dis 2009; 27: 252-258 [PMID: 19786749 DOI: 10.1159/000228558]
5. Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, Forti G, Morini S, Hassan C, Pistoia MA, Modeo ME, Rodino' S, D'Amico T, Sebkova L, Sacca' N, Di Giulio E, Luzza F, Imeneo M, Larussa T, Di Rosa S, Annese V, Danese S, Gasbarrini A. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2010; 105: 2218-2227 [PMID: 20517305 DOI: 10.1038/ajg.2010.218]
6. Kruis W, Jonaitis L, Pokrotnieks J, Mikhailova TL, Horynski M, Bátovský M, Lozynsky YS, Zakharash Y, Rácz I, Kull K, Vcev A, Faszczyk M, Dilger K, Greinwald R, Mueller R. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Aliment Pharmacol Ther 2011; 33: 313-322 [PMID: 21138455 DOI: 10.1111/j.1365-2036.2010.04537.x]
7. Liu LL, Qin Y, Cai JF, Wang HY, Tao JL, Li H, Chen LM, Li MX, Li XM, Li XW. Th17/Treg imbalance in adult patients with minimal change nephrotic syndrome. Clin Immunol 2011; 139: 314-320 [PMID: 21450528 DOI: 10.1016/j.clim.2011.02.018]
8. Wang Y, Ito S, Chino Y, Goto D, Matsumoto I, Murata H, Tsutsumi A, Hayashi T, Uchida K, Usui J, Yamagata K, Sumida T. Laser microdissectionbased analysis of cytokine balance in the kidneys of patients with lupus nephritis. Clin Exp Immunol 2010; 159: 1-10 [PMID: 19807734 DOI: 10.1111/j.1365-2249.2009.04031.x]
9. Summers SA, Steinmetz OM, Li M, Kausman JY, Semple T, Edgtton KL, Borza DB, Braley H, Holdsworth SR, Kitching AR. Th1 and Th17 cells induce proliferative glomerulonephritis. J Am Soc Nephrol 2009; 20: 2518-2524 [PMID: 19820122 DOI: 10.1681/ASN.2009030337]